Procalcitonin in patients undergoing cardiopulmonary bypass in open heart surgery—first results of the Procalcitonin in Heart Surgery study (ProHearts)
To investigate procalcitonin (PCT) levels in patients undergoing cardiopulmonary bypass (CPB) in order to assess the prevalence and prognostic capacity of elevated PCT levels following CPB in open heart surgery.
prospective observational study in consecutive patients.
Twenty-four-bed ICU, department of thoracic and cardiovascular surgery, university hospital.
Seven hundred and twenty two patients, 691 of whom underwent CPB, i.e., 476 had coronary bypass surgery (CABG), 130 valve replacement, 34 combined CABG and valve replacement and 23 thoracic aortic surgery.
Standard perfusion techniques were used with cardioplegic arrest and mild hypothermia (28–32°C). With the exception of thoracic aortic procedures, full-flow perfusion was performed.
Measurements and results
PCT was measured prior to surgery and daily thereafter until ICU discharge or death. PCT significantly increased at day 1 postoperatively compared to baseline values (0.25±1.65 vs 6.49±22.0 ng/ml, p<0.005). However, in 55.1% of patients PCT was below 1.0 ng/ml. In 12.8% of CABG patients PCT was increased to >5.0 ng/ml, compared to 39% in valve patients and 35% of patients with aortic surgery. An elevated PCT level >1.0–5.0 ng/ml at day 1 was highly predictive of mortality (P<0.03, vs<1.0 ng/ml), with an additional accuracy when levels >5.0 ng/ml were measured (P<0.002 vs<1.0 ng/ml).
These results provide evidence that PCT might serve as an early prognostic marker in patients undergoing CPB in open heart surgery. It may be worth considering immunomodulating approaches in patients presenting elevated PCT levels in the early phase after CPB.
Key wordsCardiopulmonary Coronary artery bypass graft Valve surgery Thoracic aortic surgery Prognosis Hypotension Systemic inflammatory response syndrome (SIRS) Procalcitonin Endotoxin
- 3.Menache P, Haydar S, Peynet J (1994) One potential mechanism of vasodilatation after warm heart surgery: the temperature dependent release of cytokines. J Thorac Cardiovasc Surg 107: 293–299Google Scholar
- 6.Loebe M, Hennig E, Moller J, Spiegelsberger S, Weng Y, Hetzer R (1997) Long-term mechanical circulatory support as a bridge to transplantation, for recovery from cardiomyopathy, and for permanent replacement. Europ J Cardio Thorac Surg 11 [Suppl]: 8–24Google Scholar
- 7.Argenziano M, Choudhri AF, Salehizadeh B, et al (1997) A novel approach to the treatment of vasodilatory shock after cardiac transplantation. Circulation 96: 371 (abstract)Google Scholar
- 8.Andresen LW, Baek L, Degn H, et al (1987) Presence of circulating endotoxins during cardiac operations. J Thorac Cardiovasc Surg 93: 115–119Google Scholar
- 9.Rocke DA (1987) Endotoxinemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 93: 882–837Google Scholar
- 19.Nijsten MWN, Schraffordt Koops H, Bijzet J, van Ginkel RJ, Zwaveling JH (1998) Pro-Calcitonin levels show a very fast rise after isolated limb TNF-perfusion in oncologic patients. Intensive Care Med 24: S139 (abstract)Google Scholar
- 20.Eberhardt OK, Langefeld I, Kuse ER et al. (1998) Procalcitonin in the early phase after renal transplantation—will it add to diagnostic accuracy? Clin Transplant 12: 206–211Google Scholar
- 22.Meisner M, Tschaikowsky K, Schmidt J, Schüttler J (1996) Procalcitonin (PCT) —indications for a new diagnostic parameter of severe bacterial infection and sepsis in transplantation, immuno-suppression and cardiac assist devices. Cardiovasc Engineer 1: 67–76Google Scholar